enGene (ENGN) Expected to Announce Earnings on Monday

enGene (NASDAQ:ENGN) is expected to release its Q1 2026 results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($0.55) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:00 PM ET.

enGene (NASDAQ:ENGN) last posted its quarterly earnings results on Monday, December 22nd. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.18). On average, analysts expect enGene to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

enGene Stock Performance

NASDAQ ENGN opened at $10.11 on Monday. The firm has a market capitalization of $677.27 million, a P/E ratio of -4.41 and a beta of -0.29. The stock has a 50-day simple moving average of $9.57 and a two-hundred day simple moving average of $7.87. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.30 and a current ratio of 6.30. enGene has a fifty-two week low of $2.65 and a fifty-two week high of $12.25.

Analyst Ratings Changes

A number of brokerages recently issued reports on ENGN. Raymond James Financial raised shares of enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 price target on the stock in a report on Tuesday, November 11th. Morgan Stanley increased their target price on shares of enGene from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 12th. UBS Group lifted their price target on enGene from $4.00 to $10.00 and gave the company a “neutral” rating in a research note on Wednesday, November 12th. Citigroup reiterated a “market outperform” rating on shares of enGene in a research report on Monday, January 5th. Finally, Citizens Jmp boosted their price objective on enGene from $18.00 to $21.00 and gave the company a “market outperform” rating in a research report on Wednesday, November 12th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, enGene presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.29.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new stake in shares of enGene during the fourth quarter worth $216,000. Vestal Point Capital LP grew its stake in enGene by 185.1% during the 4th quarter. Vestal Point Capital LP now owns 1,055,000 shares of the company’s stock valued at $9,527,000 after acquiring an additional 685,000 shares in the last quarter. Virtus Investment Advisers LLC purchased a new stake in enGene during the 4th quarter valued at about $284,000. Quadrature Capital Ltd acquired a new stake in enGene in the 4th quarter valued at about $439,000. Finally, Millennium Management LLC lifted its stake in enGene by 7,214.0% in the 4th quarter. Millennium Management LLC now owns 1,499,520 shares of the company’s stock worth $13,541,000 after purchasing an additional 1,479,018 shares in the last quarter. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Company Profile

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.